Company / R&D Expense
Tvardi Therapeutics, Inc. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$91.9M
FY2024
5-year range
$75.5M / $113.8M
FY2020-FY2024
Trend
+11.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2024 after 2 years of decline, reaching $92M.
Based on SEC 10-K filings.
$92M in FY2024 with a 5-year CAGR of +13.6%.
Declined from $108M to $92M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -6.9%
- 5-Year CAGR
- +13.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +13.6%, indicating consistent growth.
- In FY2024, r&d expense increased 11.1% year-over-year.
- Peak r&d expense was recorded in FY2021.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $91.9M | +11.1% |
| FY2023 | $82.7M | -23.3% |
| FY2022 | $107.9M | -5.2% |
| FY2021 | $113.8M | +50.7% |
| FY2020 | $75.5M | +55.7% |
| FY2019 | $48.5M | -1.5% |
| FY2018 | $49.3M | +132.1% |
| FY2017 | $21.2M | +40.8% |
| FY2016 | $15.1M | +73.5% |
| FY2015 | $8.7M | +88.9% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026